Cosmos Health Inc. (COSM)
| Market Cap | 25.52M +11.1% |
| Revenue (ttm) | 73.73M +33.8% |
| Net Income | -24.39M |
| EPS | -0.57 |
| Shares Out | 100.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,540,707 |
| Open | 0.2548 |
| Previous Close | 0.2532 |
| Day's Range | 0.2452 - 0.2731 |
| 52-Week Range | 0.1616 - 1.3200 |
| Beta | 4.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 18, 2026 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), N... [Read more]
Financial Performance
In 2025, Cosmos Health's revenue was $65.27 million, an increase of 19.93% compared to the previous year's $54.43 million. Losses were -$19.14 million, -14.45% less than in 2024.
Financial StatementsNews
Cosmos Health secures five-year contract manufacturing agreement
Cosmos Health’s (COSM) Cana Laboratories secured a new five-year contract manufacturing agreement with Viofar covering approximately 2.5M units of ROSARTIA. The agreement represents approximately 500,...
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presenc...
Cosmos Health launches C-ScrubVet in the UK
Cosmos Health (COSM) has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet. C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial…
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and suppli...
Cosmos Health: A Company Transformed — 2026 Year-to-Date
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1...
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital st...
Cosmos Health sees over $6M in incremental annual U.S. revenue from Oliv18
Cosmos Health (COSM) announced it is projecting Oliv18 to generate over $6M in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3M in gross profit…
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.
Cosmos Health announces distribution agreement with Innova Healthcare
Cosmos Health (COSM) announced an exclusive distribution agreement with Innova Healthcare covering the Company’s proprietary Sky Premium Life range of food supplements across the Kingdom of Saudi Arab...
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term
Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued pro...
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a fr...
Cosmos Health expands Sky Premium Life distribution pact with Pharma Cell
Cosmos Health (COSM) announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. Building on the partnership the companies launched…
Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are dist...
Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases
CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it h...
Cosmos Health announces repurchase of additional 250,000 shares
Cosmos Health (COSM) announced that it has repurchased an additional 250,000 shares of its common stock in the open market at an average price of approximately 27.82c per share. The…
Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it ...
Cosmos Health announces repurchase of additional 100,000 shares
Cosmos Health (COSM) announced that it has repurchased an additional 100,000 shares of its common stock in the open market at an average price of approximately 29.28c per share. The…
Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases
CHICAGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it h...
Cosmos Health stock buyback expands to 4.49M shares
Cosmos Health (COSM) announced that it has repurchased an additional 133,000 shares of its common stock in the open market at an average price of approximately 29.8c per share. The…
Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases
CHICAGO, July 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it h...
Cosmos Health repurchases additional 215,000 common shares in open market
Cosmos Health (COSM) announced that it has repurchased an additional 215,000 shares of its common stock in the open market at an average price of approximately 32.5c per share. The…
Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases
CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it h...
Cosmos Health reports Libytec partnership to commercialize Diabit-IS X in Greece
Cosmos Health (COSM) announced that it has entered into an agreement for the commercialization of its type-2 diabetes medication DIABIT-IS X in the Greek market, through a distribution and promotion…
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a pres...